-

OPCH INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Option Care Health, Inc.

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP continues its investigation on behalf of Option Care Health, Inc. (“Option Care Health” or the “Company”) (NASDAQ:OPCH) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws and other unlawful business practices.

[LEARN MORE ABOUT THE INVESTIGATION]

What Happened?

On February 24, 2026, Option Care Health announced fourth quarter 2025 earnings. On the earnings call, the Company’s guidance included a disclosed Stelara biosimilar gross-profit headwind of $25 million to $35 million for FY 2026. The Company also gave full year 2026 revenue guidance of $5.8B-$6.0B. CEO John Rademacher stated: “We are confident in the guidance we are putting forth and look forward to continuing our track record of execution.”

On April 30, 2026, Option Care Health released its first quarter 2026 financial results, including revenue of only $1.35 billion (a 1.3% increase year over year) missing consensus estimates, as well as net income of $45.3 million, down 3.0% year over year, and an adjusted EBITDA of $104.8 million, down 6.3% year over year. The Company also lowered its full year 2026 guidance for revenue from $5.8B-$6.0B to $5.675B - $5.775B. The Company blamed its reduced guidance on “lower CID patient retention and therapy mix.” On this news, the price of Option Care Health shares declined by $6.54 per share, or approximately 24%, from $26.87 per share on April 29, 2026 to close at $20.33 on April 30, 2026.

What Should I Do?

At this stage, no lawsuit has been filed. The investigation is ongoing to determine whether claims may be brought under federal securities laws.

If you purchased or otherwise acquired Option Care Health securities, have information, or would like to learn more about this investigation, please contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below, to discuss your rights or interests with respect to these matters at no cost.

[LEARN MORE ABOUT SECURITIES CLASS ACTIONS]

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Kirby McInerney LLP
Lauren Molinaro, Esq.
212-699-1171
https://www.kmllp.com
https://securitiesleadplaintiff.com/
investigations@kmllp.com

Kirby McInerney LLP

NASDAQ:OPCH

Release Versions

Contacts

Kirby McInerney LLP
Lauren Molinaro, Esq.
212-699-1171
https://www.kmllp.com
https://securitiesleadplaintiff.com/
investigations@kmllp.com

More News From Kirby McInerney LLP

UNCY INVESTOR REMINDER: Unicycive Therapeutics, Inc. Investors Have Until November 2, 2026 To Contact Kirby McInerney LLP to Seek Lead Plaintiff Role

NEW YORK--(BUSINESS WIRE)--If you have suffered a loss on your Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (NASDAQ: UNCY) investment, contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below to discuss your rights or interests in the securities fraud class action lawsuit at no cost.Investors have until November 2, 2026 to ask the Court to appoint them as lead plaintiff. Courts do not consider applications filed after...

YSS INVESTOR REMINDER: York Space Systems Inc. Investors Have Until October 30, 2026 To Contact Kirby McInerney LLP to Seek Lead Plaintiff Role

NEW YORK--(BUSINESS WIRE)--If you have suffered a loss on your York Space Systems Inc. (“York” or the “Company”) (NYSE: YSS) investment, contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below to discuss your rights or interests in the securities fraud class action lawsuit at no cost. Investors have until October 30, 2026 to ask the Court to appoint them as lead plaintiff. Courts do not consider applications filed after this deadli...

BBNX INVESTOR ALERT: Securities Class Action Filed Against Beta Bionics, Inc. – Investors Encouraged to Contact Kirby McInerney LLP

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NASDAQ: BBNX) securities during the period of July 30, 2025 through February 24, 2026, inclusive (“the Class Period”). Investors are encouraged to contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below to discuss your rights or i...
Back to Newsroom